

Flu is all around

Cornelia Adlhoch, Principal expert respiratory viruses, ECDC EURL meeting, Parma, 2 October 2023

Seasonal influenza activity, EU/EEA 2017-2023



Slightly earlier seasonal influenza activity compared to seasons 2017 onwards Lower positivity with only 42% maximum positivity compared to >60% in earlier seasons Influenza activity returning to pre-COVID-19 pandemic timing



Sentinel surveillance system, EU/EEA 2020-2023



Sentinel influenza surveillance systems are based on syndromic influenza-like illness (ILI) or acute respiratory illness (ARI) case definition for testing. Countries integrated COVID-19 monitoring and testing but challenges remain



Circulating types and subtypes/lineages, EU/EEA 2023/24

Influenza virus positivity and detections by type, subtype/lineage and week - EU/EEA, season 2022/2023

Early A/H3 season Later and long H1/pdm09 and B/Vic circulation



Influenza virus detections by type, subtype/lineage and week - EU/EEA, season 2022/2023



© European Centre for Disease Prevention and Control 2022 Reproduction is authorised, provided the source is advnowledged.

Dominant virus type, EU/EEA 2022/23





							None	None	None	None	A(Hs)	A(Hs)	A(Ha)	A(Hs)	A(Ha)	A(Hs)	A and B	A and B	A and B	1.1	E/Ve	8/114	8,154	1	B/Via	8,154	E/Ve								•		
						•					Aand B	A(Hs)	A and B				•									•										-	
	•				÷		•				A	٨	None	A	A(Hs)pdm0p	٨	A(H1)pdm00	A(Hs)pdm09	A(Hs)ødmoa	A(H1)pdm09	None	None		8/Vir	B/Via	8,114	None	None	None	None	None	None	None	Nane	None	None	
	•				•		•	•		A(H1)pdm09	A(Hz)pdm09	A(H1)pdm09	A(H1)pdm09	A(Hs)pdm09	A(Hs)pdm0p	AHAIpdm08	A(H1)pdm09	A(H1)pdm09	A(Hs)pdm09	A(H4)pdm09	E/Vie	8/Vie	B/Via	E/Ve	8,Via	B/Va	E/Ve	E/Vie		E/Vie					· · ·		
	None	None	Nors	None	None	Non.	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	Nane	None	None								
	None	None	None	None	None	None	None	None	None	None	A(Hs)pdm09	A(H1)pdm00	None	None	None	A(H4)pdm08	A(Hs)admoa	1	A(Hs)adm0a	1	1	None	8	A(H1)pdm00	E.	8	None	None	Nane	None	None	None	None	None	Nana	Nana	
		None	None	None	None	None	Α.	A(Ha)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hd)	A(Hs)	×	٨	٨	None	None	None	None	None	None	None	B/Vie	B/Via	E/Ve	E/Vie	None	8/1/4	None	None	None	None	None	None	
	None	None	None	None	None	None	None	A(Hs)	A(Hs)	A(Ha)	A(Hs)	A(Hs)	A(Ha)	A(HS)	A(Ha)	A and B	A(Ha)	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	
				•					A(Hs)	A(Ha)	A(Hb)	A(Ha)	A(Ha)	A(Hs)	A(Ha)	A(Ha)	AandiB	Awed B	8	1	1	1	8	8	8	8	8	1		•	•						
	A(Hs)	A(Hs)	A(Ha)	A(Hs)	A(Hs)	A(Ha)	A(Hs)	A(Hs)	A(Hs)	A(Ha)	A(Hb)	A(Hs)	A(Ha)	A(Hd)	A(Ha)	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	
	A(Hs)pdm09	A(Hs)pdm09	A(Ha)	A(Hs)	A(Hs)	A(Hs)	A(Ha)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	None	A(Hs)	E/Ve	A(Hs)	8/Vie	S/Vie	E/Vie	E/Via	B/Via	E/Vie	8/Vie	8/Via	8/Vie	E/Vie	8,Via	A(H4)pdm09	E/Vie	Nane	8/Vie							
	None		None	None	None	None		None	None	None	None	None	None	*	None	٨	A(Hs)pdm09	A	٨	A(H1)pdm00	A(Hs)pdm00	A(Hs)pdm09	A(H1)pdm00	A(Hs)pdm09	A(Hs)pdm09	B/Vie	E/Vie	E/Vie	B/Vie	8/Vie	None	None	None	•	•	-	
	•		A	A	Å	٨	A(Hs)pdm09	A(Hs)pdm09	A(H1)pdm09	A(H1)pdm09	A(Hs)pdm09	A(H1)pdm09	A(H1)pdm09	•	A(Hs)pdm09		•	E/Vie	6/Vie	E/Vie	E/Vie	B/Vie	E/Via	E/Vii	E/Vie	8,154	E/Vir	E/Vie	8/Via			•	None	None	None		
	None	None	None	None	None	Nane	None	A	Å	A	A	A	A	A	<u>.</u> A	Å	A	None	8	1		1	8	None	8	8	None	None	None	None	None	None	None	None	None	None	
	None	None	None	None	None	None	None			None	A	A	A(Ha)	A(Hs)	A(Ha)	A	A	٨		A(H1)pdm09	A	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	
	None	None	None	None	None	Nane	A(Hs)	A(Hs)ødm09	A(H1)pdm0a	λ.	A	٨	*	A	A	٨	A	A	•	E/Ve	E/Ve	8/Vie	8/Via	S,Vie	6,Vie	\$,Via	E/Vie	8/Vie	8/Vie	None	None	None	None	None	None	None	
	A	None	٨	A	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(HS)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	None	A and B	6	6	1	8	1	8	5	8	8	8	5	8	None	None	None	None	None	None	None	
	A(Hs)	A(Hs)	A(Hs)	A(HS)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(H5)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hs)	A(Hs)edm09	1	8	E	Aand B	8	None	A(Hs)pdm09	8		None	None	None	None	Nane	None	
	A(Hs)pdm09	A(H1)pdm09	A(H1)pdm00	^	A(Hs)		A(H1)pdm00	A(Hs)	A	A .		A.	A(HL)pdm09	A(HL)pdm00	A(Hs)pdm09	A(HL)pdm09		A(H1)pdm0p	A(H1)p6m09	A(H1)pdm00	A(H1)pdm09	A(H1)pdm09	A(H1)pdm09	A(Hs)pdm00	A(Hs)pdm02	~	^	A and E		^		1	*	A.	A.	None	
	^	^	~	^	^	V(HT)bewoe	X(H1)pdm0p	A(H1)pdm0p	A(H1)pamae	A(HL)pembe	A(H1)pdm0p	A(H1)pdm09	V(HI)pamos	A(ML)pidmop	A(H1)pdm0p	^	^	^	^	Asses		5/110	5/112	1.14	8,518	A, 114	E. Vie	1/11	8,718	2,718	S/Vid	8, 118	3,112		-	1, 10 C	
	None	None	Tione Anto	47443	None Alter	45940	A(H5)	A	0		A	A		A	A.	A.	A		A North	A.			5	-		5				-		a line	None	-	a line	None	
	None	Nere	N(ns)	N(NG)	New	Nasa	Nors)	N(NG)	New		n(no)	(ma)				A second							Auna					1	Acres 8				Nees				
	No.	New	Need	New	Need	Need	Need	here.	No.	Nees	Nees.	Nees						Nees	Need	Nees				Nees				New		No.	New	New	Nees	No.	New	New	
										4044							A Malada M	1/Hilada 10		And		And a		1.14	8.V.	1.14	E.V.	1.0					2.02				
	Alter	Alter	Altel	A/Hs)	Alter	ATHE	Alter	Altal	After	Attal	A(Ha)	ATHS	ADIa	A/Hst	ATHO		Aundi	Aand B			1			1				1	1	1				14442	Nene	Name	
						A	Å	A	A.	A	A	A	A.	A	A	À					Ands	Andi	Ands	And													
022.																																					

Week Q

2022-10

Country Q

Austria Lalain

Lebrie

atherla Nerve Palana Partuge Remani Simultie Sleveni

Source: www.flunewseurope.org

Influenza types, subtypes/lineages in hospitals, EU 2023/24



Early A/H3and later H1/pdm09 and B/Vic circulation reflected in hospital data with substantial hospitalisations due to influenza B

Influenza detections by virus type, subtype/lineage from severe acute respiratory infection (SARI) surveillance in hospitals - EU/EEA, season 2022/2023



♥ World Health Organization 2022.
♥ European Centre for Disease Prevention and Control 2022.
Reproduction is authorised, provided the source is acknowledged.



Human cases due to avian influenza



Subtype	Cases detected in 2023	Total cases (deaths)	Countries reporting human cases				
A(H3N8)	1 case, China	3 (1)	China				
		since 2022					
A(H5N1)	8 cases/detections:	878*(458)	23 countries, including one				
	Clade 2.3.4.4b: United Kingdom (4), Chile (1), China (1)	Since 2004	EU/EEA country: Spain*.				
	clade 2.3.2.1c: Cambodia (2)	<i>*includes detections due to suspected environmental contamination in 2022 from Spain (2) and the United States (1) and in 2023 from the United Kingdom (3)</i>					
A(H5N6)	4 cases, China	88 (34)	No EU/EEA country; China (84),				
		Since 2014	Laos (1)				
A(H9N2)	5 H9N2 cases, China	126 (2)	No EU/EEA country; China (113),				
	1 H9Nx case, China	Since 1998	Egypt (4), Bangladesh (3), Cambodia (2), Oman (1), Pakistar (1), India (1), Senegal (1)				

Source: WHO, ECDC line list, Investigation into the risk to human health of avian influenza (influenza A H5N1) in England: technical briefing 5 - GOV.UK (www.gov.uk); cumulativenumber-of-confirmed-human-cases-for-avian-influenza-a(h5n1)-reported-to-who--2003-2023.pdf; CHP closely monitors human case of avian influenza A(H5N6) in Mainland (info.gov.hk)

Symptoms of human cases (truly*) infected with avian influenza H5N1 (clade 2.3.4.4b,) reported 2022-2023



Chile: 53year old man, <u>exposure unclear (environmental?</u> to infected birds/seals close to his home), no comorbidities, cough, sore throat, and hoarseness, hospitalised with worsening symptoms, dyspnoea, pneumonia, admitted to ICU and mechanical ventilation

China:

- 38year old female, exposure to backyard poultry, hospitalised with severe pneumonia, passed away
- 53year old female, exposure to backyard poultry, hospitalised with severe pneumonia, recovered

Ecuador: 9year old girl, <u>contact with backyard poultry</u> (chickens and ducks), no comorbidities, conjunctival pruritus and coryza, hospitalised persistent symptoms including nausea, vomiting and constipation, treatment for encephalitis, admitted to ICU, non-invasive mechanical ventilation

Vietnam: 4year old girl, <u>exposure to backyard chicken and ducks</u>, symptoms cough, fever and jaundice, hospitalised, developed renal and liver failure, admitted to ICU

*excluding H5N1 detections in people involved in culling operations in the US, UK and Spain where contaminations are more likely, and cullers did not report symptoms or very mild symptoms (fatigue, sore throat)

Source: Human infection caused by avian influenza A(H5) - Ecuador (who.int); Human Infection caused by Avian Influenza A (H5N1) - Chile (who.int); Assessment of risk associated with recent influenza A(H5N1) clade 2.3.4.4b viruses (who.int); influenza-at-the-human-animal-interface-summary-and-assessment--from-6-october-to-11-november-2022.pdf (who.int) Full article: Clinical features of the first critical case of acute encephalitis caused by the avian influenza A (H5N6) virus (tandfonline.com); https://cdn.who.int/media/docs/default-source/influenza/who-influenza recommendations/vcm-northern-hemisphere-recommendation-2023-2024/20230224_zoonotic_recommendations.pdf?sfvrsn=38c739fa_4 MEDIA: https://bnonews.com/index.php/2023/03/china-reportshuman-case-h5n1-bird-flu/; influenza-at-the-human-animal-interface-summary-and-assessment--from-27-january-to-3-march-2023.pdf (who.int) 8

ECDC Public Health Risk Assessment for A(H5N1)

- Transmission to humans are rare events
- No human-to-human transmission
- Sporadic human infections with severe disease cannot be excluded

ECDC risk assessment:

The risk of human infection due to avian influenza viruses of the currently circulating clade 2.3.4.4b in Europe is assessed as **low** for the general population and **low to moderate** for people occupationally or otherwise exposed (including exposed to infected domesticated pets).

Avian influenza A(H5N1) clade 2.3.4.4b



- With autumn bird migration, avian influenza A(H5N1) clade 2.3.4.4b virus outbreaks are expected to continue and spread geographically across the EU/EEA.
- Transmission of avian influenza viruses to poultry farms and sporadic infections among various wild, domesticated and farmed mammals <u>will likely continue</u>.
- Whenever avian influenza viruses are present the possibility of transmission to humans cannot be excluded, particularly for directly exposed people not wearing protective equipment.
- No human infection identified in EU/EEA.



Guidance for surveillance on avian influenza in humans during the summer 2023 and winter epidemic 2023/24

Recommendation on enhanced hospital surveillance for detecting avian influenza infections – summer 2023



Overall strengthening surveillance for sporadic severe human infections with avian influenza virus in hospital <u>during summer period 2023</u> (weeks 21-39):

- Hospitalised patients with unexplained viral encephalitis/meningoencephalitis lacking the aetiological agent should be considered for testing for influenza virus.
- All influenza A positive samples from hospitalised patients should be subtyped for seasonal influenza viruses (H1N1pdm09 and H3N2).
- Samples positive for influenza type A virus but negative for A(H1N1)pdm09 or A(H3N2) should be immediately sent to the national influenza reference laboratories for further analysis and H5 testing.

Influenza testing and outlook to 2023/24 season



During the winter months when seasonal influenza viruses are circulating in the population, testing and subtyping approaches for avian influenza virus need to be **proportionate** to the epidemiological situation and the capacities of reference laboratories.

EU/EEA 2022/23



Non-sentinel tested:1.9 mio



Suggested overall surveillance approach



In areas with ongoing avian influenza outbreaks,

a <u>risk-based targeted approach</u> is proposed,

focussing on outbreaks and severe respiratory or unexplained neurological disease.

Suggestions for avian influenza surveillance



- Include recall of **exposure** to sick or dead animals in **clinical history** for patients hospitalised with respiratory symptoms. Exposure risk assessment by the clinician to inform testing decision. Specimens from hospitalised patients with very severe influenza virus infection considered for sub-typing, particularly if nosocomial outbreak.
- Test hospitalised patients with unexplained viral encephalitis/meningoencephalitis for seasonal influenza virus. Subtype type A virus positive specimens to rule out avian influenza.
- Investigate **clusters** of severe respiratory infections requiring hospitalisation and test for avian if routine testing for respiratory pathogens is inconclusive.
- Consider **wastewater** surveillance as an additional monitoring system locally, although very limited experience so far to identify low-level circulation of zoonotic influenza virus infections in the population.



Questions?

Human A(H5N1) cases and detections reported, 2003-2023 n=(878)



Source: WHO, ECDC line list, Investigation into the risk to human health of avian influenza (influenza A H5N1) in England: technical briefing 5 - GOV.UK (www.gov.uk): cumulative-number-of-confirmed-human-cases-for-avian-influenza-a(h5n1)-reported-to-who--2003-2023.pdf



Source: WHO, ECDC line list, Investigation into the risk to human health of avian influenza (influenza A H5N1) in England: technical briefing 5 - GOV.UK (www.gov.uk): cumulative-number-of-confirmed-human-cases-for-avian-influenza-a(h5n1)-reported-to-who--2003-2023.pdf